AstraZeneca Plc $AZN Stock: Keybank National Association OH Reduces Position

Keybank National Association OH decreased its position in shares of AstraZeneca Plc (NYSE:AZN) by 14.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,946 shares of the company’s stock after selling 6,198 shares during the period. Keybank National Association OH’s holdings in AstraZeneca were worth $6,127,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. Amundi boosted its holdings in shares of AstraZeneca by 6.7% in the second quarter. Amundi now owns 16,422,784 shares of the company’s stock valued at $3,114,088,000 after acquiring an additional 1,036,635 shares during the period. Janus Henderson Group PLC grew its position in shares of AstraZeneca by 889.9% during the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock worth $2,319,947,000 after acquiring an additional 10,742,268 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of AstraZeneca by 208.6% in the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock valued at $2,048,417,000 after acquiring an additional 7,021,126 shares during the period. Rathbones Group PLC increased its holdings in shares of AstraZeneca by 106,772.0% in the 1st quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after acquiring an additional 8,047,406 shares during the period. Finally, Allianz Asset Management GmbH increased its holdings in shares of AstraZeneca by 2.5% in the 2nd quarter. Allianz Asset Management GmbH now owns 6,690,300 shares of the company’s stock valued at $1,252,044,000 after acquiring an additional 160,339 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.6%

AstraZeneca stock opened at $184.46 on Friday. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71. The stock has a 50 day moving average of $168.42 and a two-hundred day moving average of $180.21. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $286.08 billion, a price-to-earnings ratio of 26.09, a PEG ratio of 1.44 and a beta of 0.24.

AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.19. The company had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The company’s revenue was up 6.5% on a year-over-year basis. During the same period last year, the business posted $2.38 EPS. As a group, research analysts expect that AstraZeneca Plc will post 10.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AZN. CICC Research started coverage on shares of AstraZeneca in a research report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Zacks Research raised shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Nordea Equity Research raised shares of AstraZeneca from a “sell” rating to a “buy” rating in a research report on Tuesday, October 13th. Wall Street Zen upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Royal Bank Of Canada started coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating for the company. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.